Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, Xu C: Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021, 178 (2): 239-261.
Talkar SS, Patravale VB: Gene Therapy for Prostate Cancer: A Review. Endocr Metab Immune Disord Drug Targets. 2021, 21 (3): 385-396.
Šamija I, Fröbe A: CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER. Acta Clin Croat. 2019, 58 (Suppl 2): 76-81.
Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M, Yamanaka H, Namiki M: The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol. 2006, 176 (6 Pt 2): S47-9.
Abraham-Miranda J, Awasthi S, Yamoah K: Immunologic disparities in prostate cancer between American men of African and European descent. Crit Rev Oncol Hematol. 2021, 164 (): 103426.
de Vrij J, Willemsen RA, Lindholm L, Hoeben RC, Bangma CH, Barber C, Behr JP, Briggs S, Carlisle R, Cheng WS, Dautzenberg IJ, de Ridder C, Dzojic H, Erbacher P, Essand M, Fisher K, Frazier A, Georgopoulos LJ, Jennings I, Kochanek S, Koppers-Lalic D, Kraaij R, Kreppel F, Magnusson M, Maitland N, Neuberg P, Nugent R, Ogris M, Remy JS, Scaife M, Schenk-Braat E, Schooten E, Seymour L, Slade M, Szyjanowicz P, Totterman T, Uil TG, Ulbrich K, van der Weel L, van Weerden W, Wagner E, Zuber G: Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther. 2010, 21 (7): 795-805.
Lee E, Ha S, Logan SK: Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. PLoS One. 2015, 10 (10): e0141589.
['Atassalang: medis']
["Iyyae situs web e ripassedia untu' akkatta-akkatta pendidikan nenniya informasi bawang na de'na mabbere saran medis iyarega layanan profesional."]
["Rilaleng iyyae, jaringang saraf iya makkewassele bali lao ri pakkutanae, de'na coco narekko engka assisompungenna sibawa angke. contona, egana tau iya riruntue sibawa lasa mattentu."]
["Tuli sappai pangajana doktere'mu iyarega pajjama kesehatang laingnge iyya engkae kualifikasi'e ri tujunna keadaang medis'e. Aja' naengka muwallupai pangajana doktere' iyarega matengnge ri laleng sappa'na nasaba engka aga pura mubaca ri situs web'e. Narekko muwasengngi engka passaleng medis iya parellu'e ripassappa, mobbii 911 iyarega lao ri ruang darurat kaminang macawe'e masitta'. De gaga assisompungeng doktere-pasien iyya ripancaji pole situs web'e iyarega akkegunanna. BioMedLib iyarega pajjamana, iyarega muwi niga pattarima lao ri situs web'e, de nawerengngi aga-aga, manessa iyarega tersirat, ri tujunna kareba iyya riyabbere'e iyarega akkegunanna."]
['Disclaimer: hak cipta']
["Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the DMCA) mabbere daya tarik lao ri punnana hak cipta iya mateppe'e majeppuu agaaga iya engkae ri Internet naruntu'i hakna ri yawa hukung hak cipta AS. "]
["Narekko mateppe'ko sibawa makessing majeppuu agaaga lise'na iyarega agaaga iya engkae ri laleng situs web iyarega jasae naruntu'i hak cipta'mu, iko (iyarega agenna) wedding kiringki pappaseng iyya naeloriwi lise' iyarega agaaga ripassu, iyarega akses lao ri iyyae ritongkoi."]
["DMCA parellu i nawereng pappaseng mu ri palanggarang hak cipta nawereng i pappaseng iyyae: (1) pappaseng pole ri jama-jamang hak cipta iyyae mancaji pakkitanna palanggarang iya nawereng i; (2) pappaseng pole ri konten iya nawereng i nenniya pappaseng iya genne'e untu' nawereng i onrong konten e; (3) pappaseng assisumpungemmu, matame' alamat, nomoro' telepon, nenniya alamat emailmu; (4) pappaseng pole ri iko makkedae iko mateppe'i majeppu konten iya engkae rilalenna pappaseng iyya mu nawereng i de'na ripalaloi pole ri punnana hak cipta, iyarega agen na, iyarega pole ri hukum e; "]
["(5) seddi pappaseng pole ri iko, ritanrai ri yawa pahukkungeng sabbi bellé, makkeda kareba ri laleng pappasengnge coco'i sibawa iko mappunnaiwi otoritas untu' napake hak cipta iya rituntut pura rikalang;"]
["nenniya (6) tanrang lima fisik iyarega elektronik pole punnana hak cipta iyarega tau iya ripalalo e untu' majjama ri laleng asenna punnana hak cipta e. "]
There are several treatment options available for prostate cancer, depending on the stage and aggressiveness of the cancer, as well as the patient's overall health and personal preferences.
Some common treatments include:
1. Active surveillance: This approach involves closely monitoring the cancer with regular checkups and tests, rather than immediately starting treatment.
It may be suitable for men with low-risk prostate cancer.
2. Surgery: A prostatectomy is a surgical procedure to remove the prostate gland.
It can be done through open surgery or laparoscopically (using small incisions and specialized tools).
3. Radiation therapy: This treatment uses high-energy radiation to kill cancer cells.
It can be delivered externally (from a machine outside the body) or internally (through implants placed near the tumor).
4. Hormone therapy: This treatment reduces the levels of male hormones (androgens) in the body, which can slow or stop the growth of prostate cancer.
It can be used alone or in combination with other treatments.
5. Chemotherapy: This treatment uses drugs to kill cancer cells.
It may be used for advanced prostate cancer that has spread to other parts of the body.
6. Immunotherapy: This treatment helps the immune system fight cancer.
It may be used for advanced prostate cancer that has not responded to other treatments.
7. Targeted therapy: This treatment targets specific genes or proteins that help cancer cells grow and survive.
It may be used for advanced prostate cancer that has not responded to other treatments.
8. Cryotherapy: This treatment uses extreme cold to freeze and kill cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
9. High-intensity focused ultrasound (HIFU): This treatment uses high-frequency sound waves to heat and destroy cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
10. Watchful waiting: This approach involves closely monitoring the cancer with regular checkups and tests, but not starting treatment unless symptoms appear or change.
It may be suitable for older men with slow-growing prostate cancer and other serious health conditions.
It is important to discuss all treatment options with a healthcare team to determine the best course of action for each individual case.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
